BeOne Medicines (ONC) Accumulated Expenses (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Accumulated Expenses data on file, last reported at $1.1 billion in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 55.93% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 55.93% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 38.0% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $1.1 billion, down from $1.1 billion in the prior quarter.
• Over the last five years, Accumulated Expenses for ONC reached as high as $1.1 billion in Q4 2025 and fell as low as $386.0 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $674.7 million across 5 years, with a median of $646.5 million in 2024.
• Across the five-year window, Accumulated Expenses grew 0.17% in 2023 and surged 55.93% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $619.5 million in 2022, then climbed by 11.99% to $693.7 million in 2023, then gained by 15.85% to $803.7 million in 2024, then soared by 38.0% to $1.1 billion in 2025, then slipped by 2.69% to $1.1 billion in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.0 billion in Q3 2025.